
Journal of International Obstetrics and Gynecology ›› 2026, Vol. 53 ›› Issue (1): 12-17.doi: 10.12280/gjfckx.20251161
• Research on Gynecological Malignancies: Review • Previous Articles Next Articles
Received:2025-10-16
Published:2026-02-15
Online:2026-03-11
Contact:
PING Yi
E-mail:pingyi7110@126.com
XU Tian, PING Yi. Research Progress on Non-Coding RNAs Regulation of Ferroptosis in Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2026, 53(1): 12-17.
Add to citation manager EndNote|Ris|BibTeX
| [1] |
Bukłaho PA, Kiśluk J, Wasilewska N, et al. Molecular features as promising biomarkers in ovarian cancer[J]. Adv Clin Exp Med, 2023, 32(9):1029-1040. doi: 10.17219/acem/159799.
pmid: 36920264 |
| [2] | Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. doi: 10.3322/caac.21834. |
| [3] | Wang CK, Chen TJ, Tan G, et al. MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis[J]. Cancer Res, 2023, 83(2):251-263. doi: 10.1158/0008-5472.CAN-22-1159. |
| [4] | Liu D, Hu Z, Lu J, et al. Redox-Regulated Iron Metabolism and Ferroptosis in Ovarian Cancer: Molecular Insights and Therapeutic Opportunities[J]. Antioxidants(Basel), 2024, 13(7):791. doi: 10.3390/antiox13070791. |
| [5] | Bipasha M, Deepali V, Prabal D, et al. Ferroptosis: A Mechanism of Cell Death With Potential Scope in Cancer Therapy[J]. Asia Pac J Clin Oncol, 2025, 21(5):465-473. doi: 10.1111/ajco.14172. |
| [6] | Guo K, Lu M, Bi J, et al. Ferroptosis: mechanism, immunotherapy and role in ovarian cancer[J]. Front Immunol, 2024, 15:1410018. doi: 10.3389/fimmu.2024.1410018. |
| [7] |
Balihodzic A, Prinz F, Dengler MA, et al. Non-coding RNAs and ferroptosis: potential implications for cancer therapy[J]. Cell Death Differ, 2022, 29(6):1094-1106. doi: 10.1038/s41418-022-00998-x.
pmid: 35422492 |
| [8] |
Jiang Y, Saeed TN, Alfarttoosi KH, et al. The intersection of ferroptosis and non-coding RNAs: a novel approach to ovarian cancer[J]. Eur J Med Res, 2025, 30(1):300. doi: 10.1186/s40001-025-02559-7.
pmid: 40247379 |
| [9] |
Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5):1060-1072. doi: 10.1016/j.cell.2012.03.042.
pmid: 22632970 |
| [10] | Ru Q, Li Y, Chen L, et al. Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects[J]. Signal Transduct Target Ther, 2024, 9(1):271. doi: 10.1038/s41392-024-01969-z. |
| [11] | Zhou Q, Meng Y, Li D, et al. Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies[J]. Signal Transduct Target Ther, 2024, 9(1):55. doi: 10.1038/s41392-024-01769-5. |
| [12] | Zheng X, Zhang C. The Regulation of Ferroptosis by Noncoding RNAs[J]. Int J Mol Sci, 2023, 24(17):13336. doi: 10.3390/ijms241713336. |
| [13] |
Zong Y, Wang X, Cui B, et al. Decoding the regulatory roles of non-coding RNAs in cellular metabolism and disease[J]. Mol Ther, 2023, 31(6):1562-1576. doi: 10.1016/j.ymthe.2023.04.012.
pmid: 37113055 |
| [14] | Gong H, Li Z, Wu Z, et al. Modulation of ferroptosis by non‑coding RNAs in cancers: Potential biomarkers for cancer diagnose and therapy[J]. Pathol Res Pract, 2024, 253:155042. doi: 10.1016/j.prp.2023.155042. |
| [15] | Mattick JS, Amaral PP, Carninci P, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations[J]. Nat Rev Mol Cell Biol, 2023, 24(6):430-447. doi: 10.1038/s41580-022-00566-8. |
| [16] |
Cai L, Hu X, Ye L, et al. Long non-coding RNA ADAMTS9-AS1 attenuates ferroptosis by Targeting microRNA-587/solute carrier family 7 member 11 axis in epithelial ovarian cancer[J]. Bioengineered, 2022, 13(4):8226-8239. doi: 10.1080/21655979.2022.2049470.
pmid: 35311457 |
| [17] | Cao L, Wang Y, Liu J, et al. Long non-coding RNA TPT1-AS1 inhibits ferroptosis in ovarian cancer by regulating GPX4 via CREB1 regulation[J]. Am J Reprod Immunol, 2024, 92(2):e13864. doi: 10.1111/aji.13864. |
| [18] |
Jin Y, Qiu J, Lu X, et al. LncRNA CACNA1G-AS1 up-regulates FTH1 to inhibit ferroptosis and promote malignant phenotypes in ovarian cancer cells[J]. Oncol Res, 2023, 31(2):169-179. doi: 10.32604/or.2023.027815.
pmid: 37304234 |
| [19] | Wei Q, Yang Y, Wang H, et al. The mechanism of lncRNA SSTR5-AS1 promoting ferroptosis resistance and immune escape in ovarian cancer cells by recruiting STAT3 to regulate SLC7A11 expression[J]. Cancer Genet, 2025,296-297:172-181. doi: 10.1016/j.cancergen.2025.07.009. |
| [20] | Wang K, Mei S, Cai M, et al. Ferroptosis-Related Long Noncoding RNAs as Prognostic Biomarkers for Ovarian Cancer[J]. Front Oncol, 2022, 12:888699. doi: 10.3389/fonc.2022.888699. |
| [21] | Gao J, Pang X, Ren F, et al. Identification of a ferroptosis-related long non-coding RNA signature for prognosis prediction of ovarian cancer[J]. Carcinogenesis, 2023, 44(1):80-92. doi: 10.1093/carcin/bgac082. |
| [22] |
Shang R, Lee S, Senavirathne G, et al. microRNAs in action: biogenesis, function and regulation[J]. Nat Rev Genet, 2023, 24(12):816-833. doi: 10.1038/s41576-023-00611-y.
pmid: 37380761 |
| [23] |
Chhabra R, Rockfield S, Guergues J, et al. Global miRNA/proteomic analyses identify miRNAs at 14q32 and 3p21, which contribute to features of chronic iron-exposed fallopian tube epithelial cells[J]. Sci Rep, 2021, 11(1):6270. doi: 10.1038/s41598-021-85342-y.
pmid: 33737539 |
| [24] |
Lobello N, Biamonte F, Pisanu ME, et al. Ferritin heavy chain is a negative regulator of ovarian cancer stem cell expansion and epithelial to mesenchymal transition[J]. Oncotarget, 2016, 7(38):62019-62033. doi: 10.18632/oncotarget.11495.
pmid: 27566559 |
| [25] | 章迪, 屈斌, 胡彬, 等. MiR-1-3p通过靶向FZDF增强卵巢癌细胞对铁死亡的敏感性[J]. 中南大学学报(医学版), 2022, 47(11):1512-1521. doi: 10.11817/j.issn.1672-7347.2022.210800. |
| [26] | Ma LL, Liang L, Zhou D, et al. Tumor suppressor miR-424-5p abrogates ferroptosis in ovarian cancer through targeting ACSL4[J]. Neoplasma, 2021, 68(1):165-173. doi: 10.4149/neo_2020_200707N705. |
| [27] | Marjamaa A, Gibbs B, Kotrba C, et al. The role and impact of alternative polyadenylation and miRNA regulation on the expression of the multidrug resistance-associated protein 1 (MRP-1/ABCC1) in epithelial ovarian cancer[J]. Sci Rep, 2023, 13(1):17476. doi: 10.1038/s41598-023-44548-y. |
| [28] | Wu J, Zhang L, Wu S, et al. miR-194-5p inhibits SLC40A1 expression to induce cisplatin resistance in ovarian cancer[J]. Pathol Res Pract, 2020, 216(7):152979. doi: 10.1016/j.prp.2020.152979. |
| [29] | Sanger HL, Klotz G, Riesner D, et al. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures[J]. Proc Natl Acad Sci U S A, 1976, 73(11):3852-3856. doi: 10.1073/pnas.73.11.3852. |
| [30] | Zhang F, Jiang J, Qian H, et al. Exosomal circRNA: emerging insights into cancer progression and clinical application potential[J]. J Hematol Oncol, 2023, 16(1):67. doi: 10.1186/s13045-023-01452-2. |
| [31] | Yang R, Ma L, Wan J, et al. Ferroptosis-associated circular RNAs: Opportunities and challenges in the diagnosis and treatment of cancer[J]. Front Cell Dev Biol, 2023, 11:1160381. doi: 10.3389/fcell.2023.1160381. |
| [32] |
Wei W, Wang N, Lin L. Prognostic Value of hsa_circ_0007615 in Epithelial Ovarian Cancer and its Regulatory Effect on Tumor Progression[J]. Horm Metab Res, 2023, 55(11):801-808. doi: 10.1055/a-2119-3229.
pmid: 37459866 |
| [33] |
Qin K, Zhang F, Wang H, et al. circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis[J]. BMB Rep, 2023, 56(2):184-189. doi: 10.5483/BMBRep.2022-0175.
pmid: 36617466 |
| [34] | Chai B, Wu Y, Yang H, et al. Tau Aggregation-Dependent Lipid Peroxide Accumulation Driven by the hsa_circ_0001546/14-3-3/CAMK2D/Tau Complex Inhibits Epithelial Ovarian Cancer Peritoneal Metastasis[J]. Adv Sci (Weinh), 2024, 11(23):e2310134. doi: 10.1002/advs.202310134. |
| [1] | HE Qian-nan, HUANG Zi-jie, WANG Yi-fan, AN Yu-sheng, FENG Shu-xian. Research Progress on Dual-Gene Methylation Testing of PAX1/JAM3 in Management of Cervical Lesion [J]. Journal of International Obstetrics and Gynecology, 2026, 53(3): 278-284. |
| [2] | XIANG Xiao-ying, SUN Ya-ge, ZHANG Yun-feng, JIA Han, WANG Yue. Research Advances in the Immune Microenvironment and Immunotherapy for p53-Abnormal Endometrial Carcinoma [J]. Journal of International Obstetrics and Gynecology, 2026, 53(3): 285-291. |
| [3] | WANG Wei, DAI Bai, SHA Ri-na, TUO Ya. Analysis of the Role and Molecular Subtype Association of Kinesin Family Member 18B in Endometrial Carcinoma [J]. Journal of International Obstetrics and Gynecology, 2026, 53(3): 292-297. |
| [4] | WU Hua-tuo, HUANG Chun-lin, MA Yan, GE Ting, LI Li. Research Progress on the Immune Microenvironment of Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2026, 53(3): 297-301. |
| [5] | YIN Di-shuang, LI Nan, GUO Hong-xia. Collision Tumor Composed of High-Grade Endometrial Stromal Sarcoma and Endometrioid Adenocarcinoma: A Case Report [J]. Journal of International Obstetrics and Gynecology, 2026, 53(3): 311-317. |
| [6] | LIU Er-yu, REN Qing-yu, GAO Xiang. A Case of Recurrent Cervical Cancer with Vesicoenteric Fistula [J]. Journal of International Obstetrics and Gynecology, 2026, 53(3): 322-328. |
| [7] | HAN Zhao-xun, ZHOU Ye. Research Progress on Oxidative Stress Mechanisms and Antioxidant Therapy in Endometriosis [J]. Journal of International Obstetrics and Gynecology, 2026, 53(2): 125-130. |
| [8] | XU Meng-ting, LU Di, SONG Dian-rong. Research Progress in the Tumor Microenvironment of Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2026, 53(2): 188-193. |
| [9] | WEI Lin-yuan, PAN Zhong-mian, LI Li. Research Progress and Perspectives of Centrin 2 in Promoting Platinum Resistance in Epithelial Ovarian Cancer through Regulation of DNA Damage Repair [J]. Journal of International Obstetrics and Gynecology, 2026, 53(2): 194-199. |
| [10] | WANG Bing-yan, LI Feng-hu. Research Progress on the Reproductive Tract Microbiome in Cervical Cancer [J]. Journal of International Obstetrics and Gynecology, 2026, 53(2): 200-205. |
| [11] | ZHANG Yan, SONG Shu-fang. Advances in the Application of DNA Methylation in Cervical Lesions [J]. Journal of International Obstetrics and Gynecology, 2026, 53(2): 206-210. |
| [12] | WANG Ju-peng, REN Li, MA Ming-kun, ZHAO Ran, WEN Xue-hong. Expression Characteristics of KRT18 in Ovarian Cancer and Its Association with Patient Survival and Tumor Immune Microenvironment [J]. Journal of International Obstetrics and Gynecology, 2026, 53(2): 211-219. |
| [13] | FU Hai-yu, SHEN Shi-yin, CHEN Ruo-bing, YUAN Shuo, HUANG Shao-ya. Acute Hyponatremia Complicated Epilepsy Following Cisplatin Chemotherapy for Cervical Squamous Cell Carcinoma: A Case Report [J]. Journal of International Obstetrics and Gynecology, 2026, 53(2): 220-223. |
| [14] | LIU Ya-xin, BAI Ru-xue, GUO Duan-yue, PENG Yong-pai. A Case Report of Advanced Recurrent Cervical Cancer with Renal Failure Treated with Cadonilimab Combined with Chemotherapy and Bevacizumab [J]. Journal of International Obstetrics and Gynecology, 2026, 53(2): 223-227. |
| [15] | WANG Si-yao, LING Fei-fei, LI Hong-li, LIU Chang. A Case Report of Hypercalcemic Type Small Cell Carcinoma of the Fallopian Tube [J]. Journal of International Obstetrics and Gynecology, 2026, 53(2): 232-236. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
